This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.
You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/health/6713503.stm
The article has changed 9 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| Cancer-drug refund scheme backed | Cancer-drug refund scheme backed |
| (about 2 hours later) | |
| A watchdog has endorsed a scheme under which a bone marrow-cancer drug's manufacturers would refund the NHS if a patient did not respond to treatment. | |
| The National Institute for Health and Clinical Excellence is recommending multiple myeloma patients in Wales and England should get Velcade on the NHS. | |
| But it said the health service should pay for the drug only when it works. | But it said the health service should pay for the drug only when it works. |
| The scheme - the first of its kind - was proposed by drugmaker Janssen-Cilag in a bid to gain support for it. | |
| In clinical trials Velcade has been shown to slow, halt or even reverse the progression of multiple myeloma. | In clinical trials Velcade has been shown to slow, halt or even reverse the progression of multiple myeloma. |
| One trial was so promising, it was halted a year early. | One trial was so promising, it was halted a year early. |
| Under the terms of the NICE recommendation, patients showing a full or partial response to the drug would be kept on it, with the treatment funded by the NHS. | Under the terms of the NICE recommendation, patients showing a full or partial response to the drug would be kept on it, with the treatment funded by the NHS. |
| However, patients showing minimal or no response would be taken off it - and the costs would be refunded by the manufacturer. | |
| Patient access | Patient access |
| The final decision on whether to put the refund scheme into practice rests with the manufacturer and the Department of Health, with final NICE guidance expected in October. | The final decision on whether to put the refund scheme into practice rests with the manufacturer and the Department of Health, with final NICE guidance expected in October. |
| MYELOMA A debilitating form of bone marrow cancerIt is currently incurable, but treatableA cancer of the plasma cells, found in the bone marrowIncidence increasing faster than any other cancer in Western world - up 30% in 30 years20,000 myeloma patients in the UK at any one time | MYELOMA A debilitating form of bone marrow cancerIt is currently incurable, but treatableA cancer of the plasma cells, found in the bone marrowIncidence increasing faster than any other cancer in Western world - up 30% in 30 years20,000 myeloma patients in the UK at any one time |
| Andrew Dillon, NICE chief executive, said: "We are aware of the challenge that the NHS faces in ensuring that patients can access expensive, but potentially effective, treatments for life-threatening conditions such as cancer. | Andrew Dillon, NICE chief executive, said: "We are aware of the challenge that the NHS faces in ensuring that patients can access expensive, but potentially effective, treatments for life-threatening conditions such as cancer. |
| "If the drug's manufacturer accepts the proposals we are consulting on today, it will mean that when the drug works well the NHS pays but when it doesn't the manufacturer should bear the cost. | "If the drug's manufacturer accepts the proposals we are consulting on today, it will mean that when the drug works well the NHS pays but when it doesn't the manufacturer should bear the cost. |
| "All patients suitable for treatment will get the chance to see if the drug works well for them." | "All patients suitable for treatment will get the chance to see if the drug works well for them." |
| Initial draft NICE guidance recommended that Velcade should not be made widely available on the NHS. | Initial draft NICE guidance recommended that Velcade should not be made widely available on the NHS. |
| However, the watchdog changed its mind following an appeal by the manufacturer - and its suggestion of a refund scheme. | However, the watchdog changed its mind following an appeal by the manufacturer - and its suggestion of a refund scheme. |
| Move welcomed | Move welcomed |
| Eric Low, chief executive of the charity Myeloma UK, said: "We welcome the fact that these conversations have resulted in a creative way to ensure that this important cancer drug can be made available to patients. | Eric Low, chief executive of the charity Myeloma UK, said: "We welcome the fact that these conversations have resulted in a creative way to ensure that this important cancer drug can be made available to patients. |
| "However, we now need to carefully consider the details of the draft recommendation as we have concerns that it may exclude some patients who could benefit." | "However, we now need to carefully consider the details of the draft recommendation as we have concerns that it may exclude some patients who could benefit." |
| Judy Dewinter, chairman of Myeloma UK, said: "Patients around the country, including myself, are incredibly relieved that the ruling is a move in the right direction. | Judy Dewinter, chairman of Myeloma UK, said: "Patients around the country, including myself, are incredibly relieved that the ruling is a move in the right direction. |
| "This represents a major development and gives patients hope that they are one step closer to being able to access an important treatment to help them fight this complex and challenging disease." | "This represents a major development and gives patients hope that they are one step closer to being able to access an important treatment to help them fight this complex and challenging disease." |